| Literature DB >> 32113080 |
Wai Tong Ng1, June Corry2, Johannes A Langendijk3, Anne W M Lee4, Antti Mäkitie5, William M Mendenhall6, Alessandra Rinaldo7, Juan P Rodrigo8, Nabil F Saba9, Robert Smee10, Primož Strojan11, Carlos Suárez12, Jan B Vermorken13, Alfio Ferlito14.
Abstract
Up to one in four patients with nasopharyngeal carcinoma present with non-metastatic stage IV disease (i.e. T4 or N3). Distinct failure patterns exist, despite the routine adoption of contemporary treatment modalities such as intensity modulated radiotherapy and systemic chemotherapy. Concurrent chemoradiotherapy (CCRT) followed by adjuvant chemotherapy or induction chemotherapy followed by CCRT are commonly employed in this setting, with the latter emerging as the preferred option. Additionally, emerging radiation technologies like proton therapy has become available offering new opportunities for prevention of radiation-induced side effects. This article reviews not only the current treatment strategies, but also discusses novel ways to tackle this challenging disease with respect to the patterns of failure.Entities:
Keywords: Chemotherapy; Immunotherapy; Nasopharyngeal carcinoma; Prognosis; Radiotherapy; Targeted therapy
Year: 2020 PMID: 32113080 DOI: 10.1016/j.ctrv.2020.101995
Source DB: PubMed Journal: Cancer Treat Rev ISSN: 0305-7372 Impact factor: 12.111